Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "adap"

VRTX Drug Gets Approval, AGTC Surges On Biogen Deal, PFE Gets A Date With FDA
RTTNews.com

VRTX Drug Gets Approval, AGTC Surges On Biogen Deal, PFE Gets ...

Adaptimmune Therapeutics plc (ADAP) is all set to initiate an open label phase I/II study of its wholly-owned MAGE-A10 T therapeutic candidate in patients with non-small cell lung cancer, following the acceptance of the company's investigational new ... RTTNews.com, 3 days ago

68 images for adap

Philippine Daily Inquirer, 1 day ago
Mideast Time, 3 days ago
Wareable.com, 6 days ago
AIDS Foundation Of Chicago, 2 weeks ago
Tech Times, 3 weeks ago
Asiaone, 1 month ago
Straits Times, 1 month ago
American Banking News, 1 month ago
Mideast Time, 1 month ago
American Banking News, 1 month ago

Adaptimmune: FDA Accepts IND For MAGE-A10 T - Quick Facts

Adaptimmune Therapeutics plc (ADAP) announced the U.S. FDA has accepted the company's investigational new drug application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 in patients with ...
 RTTNews.com3 days ago
Mideast Time

Adaptimmune Therapeutics PLC -s Buy Rating Reiterated at Leerink Swann (ADAP)

Leerink Swann restated their buy rating on shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) in a report issued on Thursday, Market Beat reports. They currently have a $24.00 target price on the stock. ADAP has been the subject of a number of ...
 WKRB News1 day ago Adaptimmune Therapeutics PLC Given Buy Rating at Leerink Swann (ADAP)  Ticker Report3 days ago Zacks: Adaptimmune Therapeutics PLC Receives Average Recommendation of Buy from Analysts (NASDAQ:ADAP)  Ticker Report3 days ago Adaptimmune Therapeutics PLC Receives Average Rating of Buy from Analysts (NASDAQ:ADAP)  SleekMoney16 hours ago
[x]  
EuroInvestor

Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer

(GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company`s ...
 Yahoo! Finance UK and Ireland3 days ago Adaptimmune Announces Data From Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting  Pharmacy Choice1 month ago Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting  Review Seeker1 month ago Adaptimmune Announces New Additions To Senior Clinical Management  TheStreet.com1 month ago
[x]  
Ticker Report

Equities Research Analysts Ratings Reiterations for July, 2nd (AAPL, ABBV, ADAP, AEZS, AGTC, ALLY, AMBA, AMP, APOL, ATHN)

Equities Research Analysts ratings reiterations for Thursday, July 2nd: Apple (NASDAQ:AAPL) had its hold rating reissued by analysts at KeyBanc. Apple (NASDAQ:AAPL) had its buy rating reaffirmed by analysts at Cantor Fitzgerald. AbbVie (NASDAQ:ABBV) ...
 Ticker Report3 days ago

California Budget Demonstrates Commitment to HIV Prevention and Care for All Californians

Includes Key Provisions for ADAP, OA-HIPP, PrEP, Syringe Access, hepatitis C care SAN FRANCISCO, June 26, 2015—San Francisco AIDS Foundation applauds Governor Jerry Brown and members of the California State Legislature for approving a state ...
 San Francisco AIDS Foundation1 week ago Project Inform Applauds California Lawmakers for Supporting Hepatitis C and HIV Services in the 2015-16 State Budget  Project Inform1 week ago
AIDS Foundation Of Chicago

Declare ADAP an essential service ahead of government shutdown in IL

On July 1, Illinois state government will shut down if the General Assembly and Governor Bruce Rauner cannot come to an agreement on a budget. This could mean a grim future for people with HIV in Illinois, as programs like the AIDS Drug ...
 AIDS Foundation Of Chicago2 weeks ago

Weekly Investment Analysts Ratings Changes for Adaptimmune Therapeutics PLC (ADAP)

Several analysts have recently updated their ratings and price targets for Adaptimmune Therapeutics PLC (NASDAQ: ADAP): 6/1/2015 Adaptimmune Therapeutics PLC is now covered by analysts at Bank of America. They set a neutral rating and a ...
 SleekMoney2 weeks ago Investment Analysts Weekly Ratings Updates for Adaptimmune Therapeutics PLC (ADAP)  Ticker Report3 weeks ago Research Analysts Weekly Ratings Changes for Adaptimmune Therapeutics PLC (ADAP)  Mideast Time1 month ago
[x]  

Adaptimmune Therapeutics PLC -s Quiet Period To Expire Tomorrow (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC -s (NASDAQ:ADAP) quiet period is set to expire on Monday, June 15th. Adaptimmune Therapeutics PLC had issued 11,250,000 shares in its initial public offering on May 6th, AnalystRatingsNetwork.com reports. The total size ...
 Mideast Time3 weeks ago Adaptimmune Therapeutics PLC -s (ADAP) Quiet Period Will End on June 15th  SleekMoney3 weeks ago
[x]  

UNICEF-Philippines hosts global meet on Adolescent Development and Participation

This week UNICEF Philippines hosts the Global Network Meeting on Adolescent Development and Participation (ADAP). The purpose of the meeting is to develop the organization's strategic direction with regard to adolescents needs and development, with ...
 GMA News.tv1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less